PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA – A SINGLE CENTER EXPERIENCE
Autori:
Zdravko Mitrović, Ivo Radman, Igor Aurer, Duška Petranović, Fedor Šantek, Boris Labar
Sažetak
Sažetak. Primarni limfom središnjega živčanog sustava (PLSŽS) oblik je ekstranodalnog ne-Hodgkinova limfoma lokaliziranog u središnjem živčanom sustavu. Retrospektivno smo prikupili podatke o 20 bolesnika liječenih u Zavodu za hematologiju KBC-a Zagreb u posljednjih osam godina. Ukupno 13 bolesnika liječeno je visokim dozama metotreksata (4 g/m2), dok su ostali liječeni drugim kemoterapijskim protokolima ili samo zračenjem. Kompletnu remisiju postiglo je 40% bolesnika, a vjerojatnost dvogodišnjeg preživljenja iznosi 30%. Nije bilo smrtnih ishoda ili značajnih ozbiljnih nuspojava uzrokovanih terapijom. Naša iskustva pokazuju da se u bolesnika mlađih od 60 godina postiže dobar terapijski odgovor, posebno ako se liječe visokim dozama metotreksata. Stariji bolesnici, koji čine većinu oboljelih, imaju lošu prognozu bez obzira na način liječenja
Summary
Summary. Primary lymphoma of central nervous system (PCNSL) represents a distinct form of extranodal non-Hodgkin’s lymphoma localized to central nervous system. We collected data retrospectively of 20 patients with PCNSL treated at Division of Hematology of UHC Zagreb in the last eight years. A total of 13 patients received high dose methotrexate (4 g/m2) while others received other chemotherapy regimens or radiotherapy only. Complete remission rate was 40% and estimated 2-years actuarial survival was 30%. There were no treatment related deaths or significant severe adverse events. Our results are satisfactory in patients younger than 60 years, especially if treated with high dose methotrexate. Older patients, who represent majority of the patients, have dismal prognosis irrespective of treatment modality.
